A rare case study highlights a multisystem autoimmune disease that emerged with symptoms of retinopathy and alopecia following COVID-19 vaccination. This finding contributes to the understanding of potential post-vaccination autoimmune responses.

Rozanolixizumab shows promise in treating triple-seronegative myasthenia gravis, offering hope for patients with limited treatment options. Rozanolixizumab shows promise in treating triple-seronegative myasthenia gravis, offering hope for patients with limited treatment options. ... myasthenia gravis (MG) responded following the administration of rozanolixizumab (Rystiggo; UCB) in a new study,1 potentially offering hope for this subset of patients with the autoimmune disease. Still, the investigators of this study offer caution in extrapolating their results to a wider patient audience, as the patient at the center of their case study is a type not frequently included in clinical trials. The treatment protocol for the rescue therapy called for suspension if her immunoglobulin G levels dropped to below 1.0 g/L or fluctuated between 1.0 and 2.0 g/L and she had signs of infection. She completed 5 treatment cycles, all of which included 6 full doses of rozanolixizumab, and was clinically stable with no serious adverse events after the final cycle. Treatment is ongoing. Noting that their treatment criteria mirrored the protocol from the MycarinG trial ( Rozanolixizumab showed efficacy in a triple-seronegative MG patient, a rare subtype often excluded from trials, offering potential hope for this group. The patient achieved symptom control with rozanolixizumab, experiencing no severe adverse effects, despite previous treatment failures. The 28-year-old patient at the center of this case report had triple-seronegative MG refractory following repeated treatment attempts with intravenous methylprednisolone (IVMP), intravenous immunoglobulin (IVIg), and plasma exchange. This subtype of MG accounts for 10% to 15% of all MG cases, meaning this small group of patients is somewhat rare and frequently excluded from randomized controlled trials.